ETFs
K
KNSA
Kiniksa Pharmaceuticals Internat…
44.90
-0.42-0.93%After Hours: 44.90 0.00 0.00%16:40 04/17 EDT
OPEN/PREV CLOSE45.40/45.32
TODAY RANGE44.74-45.91
VOL1.01M
MARKET CAP3.45B
52 WEEK RANGE19.41-50.03
AVG VOL (3M)632.84K
% TURNOVER1.32%
TURNOVER--
P/E (TTM)60.10
% RANGE2.58%
EPS(TTM)0.7471
P/E(FORWARD)39.73
P/B6.04
BVPS7.44
DIVIDEND--
P/S5.06
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.99B
SHARES OUTSTANDING76.85M
NEXT EARNINGS04/21-05/02
FREE FLOAT44.35M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
The Motley Fool·2d ago
What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge
Dow Jones·3d ago
Kiniksa Pharmaceuticals Is Maintained at Outperform by Wedbush
TipRanks·3d ago
Kiniksa price target raised to $58 from $53 at Wedbush
Simply Wall St·04/11 22:37
A Look At Kiniksa Pharmaceuticals (KNSA) Valuation As Heart’s Home Campaign Targets ARCALYST Growth
Simply Wall St·04/09 01:34
Kiniksa’s Heart’s Home Campaign Targets ARCALYST Growth In Pericarditis Market
Reuters·04/08 20:43
Kiniksa CEO Sanj K Patel disposes 7,278 shares worth $364,673
Reuters·04/08 20:40
Kiniksa COO Ross Moat disposes of USD 152,981 in common shares
Reuters·04/08 20:35
Kiniksa director Barry Quart disposes 6,901 shares for $345,104
TipRanks·04/08 12:11
Kiniksa launches direct-to-consumer campaign for Arcalyst
Same Industry
Name/Symbol
Change%
Price